Literature DB >> 8339018

Comparative trial of clomiphene citrate/human menopausal gonadotropin and the contraceptive pill, followed by clomiphene citrate/human menopausal gonadotropin, in a gamete intrafallopian transfer program.

T F Kruger1, A Fisher, Y Swart, J P Van der Merwe, K Smith.   

Abstract

PURPOSE: It may sometimes be necessary to regulate cycles in assisted reproduction. Cycles can be regulated with gonadotropin releasing hormone (GnRHa) agonist but other methods can also be used. The aim of this study was to compare the pregnancy rate in a gamete intrafallopian transfer (GIFT) program in patients receiving a contraceptive pill/Clomid/human menopausal gonadotropin (hMG) regimen (study group), with the standard Clomid/hMG regime (control group). Fifty one patients in the study group were carefully matched for patient age, infertility diagnosis (female), semen parameters, number of follicles, and number of oocytes transferred into consideration with a control group.
RESULTS: The overall pregnancy rate was 21.6% (11/51) in the study group and 47% (24/51) in the control group (P = 0.01). However, the ongoing pregnancy rate in the two groups did not differ significantly, 11.8% (6/51) vs 27.5% (14/51) (P = 0.08). In the study group, 7.8% of patients had to be seen over a weekend, compared to 13.7% in the control group (not significant).
CONCLUSION: From the findings we conclude that, although this method of controlling cycles can be useful in selected patients, it is not the ultimate method.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8339018     DOI: 10.1007/bf01207737

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  10 in total

1.  In vitro fertilization and embryo transfer program, Department of Obstetrics and Gynecology, University of Adelaide at the Queen Elizabeth Hospital, Woodville, South Australia.

Authors:  J F Kerin; G M Warnes; P Quinn; C Kirby; R Jeffrey; C D Matthews; R F Seamark; K Texler; B Antonas; L W Cox
Journal:  J In Vitro Fert Embryo Transf       Date:  1984-03

2.  Predictive value of abnormal sperm morphology in in vitro fertilization.

Authors:  T F Kruger; A A Acosta; K F Simmons; R J Swanson; J F Matta; S Oehninger
Journal:  Fertil Steril       Date:  1988-01       Impact factor: 7.329

Review 3.  Effectiveness of treatment for infertility.

Authors:  R J Lilford; M E Dalton
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-18

4.  A fixed stimulation protocol for in vitro fertilization (IVF) without determinations of hormones in blood.

Authors:  P Kemeter; W Feichtinger
Journal:  Acta Eur Fertil       Date:  1989 Mar-Apr

5.  [Ovulation induction for in vitro fertilisation at the Tygerberg Hospital].

Authors:  J P van der Merwe; T F Kruger; C J Lombard; L M Muller
Journal:  S Afr Med J       Date:  1987-04-18

6.  The role of oocyte maturity in the treatment of infertility because of teratozoospermia and normozoospermia with gamete intrafallopian transfer.

Authors:  J P van der Merwe; T F Kruger; Y Swart; C J Lombard
Journal:  Fertil Steril       Date:  1992-09       Impact factor: 7.329

Review 7.  Induction of ovulation for assisted reproduction programmes.

Authors:  S Oehninger; G D Hodgen
Journal:  Baillieres Clin Obstet Gynaecol       Date:  1990-09

8.  Pure follicle stimulating hormone does not enhance follicular recruitment in clomiphene citrate/gonadotropin combinations.

Authors:  M M Quigley; R L Collins; J Blankstein
Journal:  Fertil Steril       Date:  1988-10       Impact factor: 7.329

9.  Gamete intrafallopian transfer: assessment of the optimal number of oocytes to transfer.

Authors:  A S Penzias; M M Alper; S P Oskowitz; M J Berger; I E Thompson
Journal:  Fertil Steril       Date:  1991-02       Impact factor: 7.329

10.  Sperm morphologic features as a prognostic factor in in vitro fertilization.

Authors:  T F Kruger; R Menkveld; F S Stander; C J Lombard; J P Van der Merwe; J A van Zyl; K Smith
Journal:  Fertil Steril       Date:  1986-12       Impact factor: 7.329

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.